Microbial Ecosystem Therapeutics (MET)

Microbial Ecosystem Therapeutics (MET) represents an innovative approach to treating diseases by restoring or modifying the human gut microbiota using complex, defined bacterial communities. Unlike conventional probiotics, which typically use single or few strains, MET employs multi-strain formulations derived from healthy donors or rationally designed ecosystems to address dysbiosis linked to various conditions. Microbial Ecosystem Therapeutics refers to standardized, defined mixtures of beneficial microbes, typically isolated from healthy donors, and formulated to restore or replace dysfunctional gut microbiota.
Petrof et al. 2013 Benef Microbes 4(1): 53-65

It is an alternative to Fecal Microbiota Transplantation (FMT), addressing standardization, safety, and regulatory concerns. Strains are carefully selected, cultured, and combined to form a reproducible, quality-controlled ecosystem, often delivered orally (e.g., Microbial Ecosystem Therapeutics 1 (MET-1) or RePOOPulate). Focuses on restoring ecosystem function and diversity, with products designed to be consistent and safe for clinical use. Regulatory Status: Developed as drug products, subject to stringent manufacturing and regulatory standards.
Allen-Vercoe & Petrof 2015 Can Commun Dis Rep 45(Suppl 5): 3-6

see also:
Microbial Ecosystem Therapeutics 1 (MET-1)
Microbial Ecosystem Therapeutics 2 (MET-2)
Microbial Ecosystem Therapeutics 3 (MET-3)
NuBiyota